Navigation Links
Synvista Therapeutics to Present at Acumen BioFin Rodman & Renshaw 5th Annual Global Healthcare Conference
Date:5/12/2008

- Presentation to be Webcast -

MONTVALE, N.J., May 12 /PRNewswire-FirstCall/ -- Synvista Therapeutics, Inc. (Amex: SYI) announced today that Noah Berkowitz, M.D., Ph.D. President and Chief Executive Officer of Synvista will present at the upcoming Rodman & Renshaw 5th Annual Global Healthcare Conference on Monday, May 19, 2008 at 12:10 p.m. CEST (6:10 a.m. EDT). The event will be held from May 19-20, 2008 at the Le Meridien Beach Plaza Hotel in Monte Carlo.

Dr. Berkowitz will discuss the company's planned and/or ongoing Phase 2 initiatives for SYI-2074 (formerly ALT-2074) in cardiovascular diseases, alagebrium in heart failure and diabetic nephropathy and progress on the company's Haptoglobin diagnostic test. He will also provide an update of recent milestones and executive appointments.

The presentation will be simultaneously webcast and can be viewed live on the investor relations section of the Company's website at http://www.synvista.com . Participants are encouraged to log on to the webcast approximately five to ten minutes prior to the start of the presentation. It will be archived there after the event.

Note to Attendees: Synvista will be available for one-on-one meetings. Please arrange through Rodman & Renshaw or by calling Kim Sutton Golodetz or Jules Abraham at Lippert/Heilshorn & Associates at 212-838-3777.

The conference will feature presentations from more than 150 public and privately held emerging growth healthcare companies presenting data on an array of therapeutic topics including oncology, cardiovascular disease, central nervous system disorders, infectious diseases and medical device technology. Details regarding the conference can be obtained at http://www.rodmanandrenshaw.com .

About Synvista Therapeutics

Synvista Therapeutics is a biopharmaceutical company developing drugs to treat and prevent cardiovascular disease and nephropathy in people with diabetes. The Company believes it has identified several product candidates that represent novel approaches to some of the largest pharmaceutical markets. The Company's portfolio includes orally bioavailable, organoselenium mimics of glutathione peroxidase. These compounds metabolize lipid peroxides and have the potential to limit myocardial damage subsequent to a myocardial infarction. The Company is developing a clinical diagnostic test, based on cardiovascular risk assessment, using Haptoglobin characterization, to identify patients at high risk for cardiovascular complications of diabetes.

Synvista Therapeutics is also developing alagebrium, a proposed breaker of AGEs for the treatment of diastolic heart failure. This disease represents a rapidly growing market of unmet medical need, particularly common among diabetic patients. Alagebrium has demonstrated relevant clinical activity in two Phase 2 clinical trials in heart failure, as well as in animal models of heart failure and nephropathy, among others. Alagebrium has been tested in approximately 1,000 patients in multiple Phase 1 and Phase 2 clinical trials, allowing Synvista Therapeutics to assemble a sizeable human safety database. For more information, please visit the Company's website at http://www.synvista.com .

Any statements contained in this press release that relate to future plans, events or performance are forward-looking statements that involve risks and uncertainties including, but not limited to, the risks associated with the events described in this press release, future clinical development of Synvista Therapeutics' product candidates, and other risks identified in Synvista Therapeutics' filings with the Securities and Exchange Commission. Further information on risks faced by Synvista are detailed under the caption "Risk Factors" in Synvista Therapeutics' Annual Report on Form 10-K for the year ended December 31, 2007. These filings are available on a website maintained by the Securities and Exchange Commission at http://www.sec.gov. The information contained in this press release is accurate as of the date indicated. Actual results, events or performance may differ materially. Synvista Therapeutics undertakes no obligation to publicly release the result of any revision to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.


'/>"/>
SOURCE Synvista Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Synvista Therapeutics to Present at the BIO InvestorForum 2007
2. Synvista Therapeutics to be Featured on Wallst.net
3. Synvista Therapeutics to Develop Topical Formulation of ALT-2074 for the Treatment of Psoriasis
4. Synvista Therapeutics to Present at the 10th Annual BIO CEO & Investor Conference
5. Synvista Therapeutics Highlights Newly Published Data Demonstrating the Value of Haptoglobin Genotype Testing In People with Diabetes
6. Synvista Therapeutics Increases Commercial Focus by Appointing David C. Tantillo Senior Director of Marketing and Sales
7. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
8. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
9. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
10. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
11. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/12/2016)... , February 12, 2016 ... Efforts by Enabling Scientific Understanding of Complex Diseases ... Rare Diseases --> ... diagnostics in South Asia and a leading provider of ... contribute $10 million to the GenomeAsia 100K consortium ...
(Date:2/11/2016)... February 11, 2016 Non-profit Consortium Aims ... Understanding to Support Research and Discovery --> ... announced an ambitious plan to sequence 100,000 individuals. It is ... and at least 7 of North and East Asian countries. ... first phase, the project will focus on creating phased reference ...
(Date:2/11/2016)... -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX ) today announced its financial ... --> --> For the fourth ... million, or $0.34 loss per share, compared to a net loss ... period in 2014. For the year ended December 31, 2015, the ... per share, as compared to a net loss of $60.5 million, ...
(Date:2/11/2016)... AUSTIN, Texas , Feb. 11, 2016  Vermillion, ... focused on gynecologic disease, today announced the formation of ... --> --> Pelvic ... in both diagnosis and management. Once pregnancy is ruled ... fallopian tubes and ovaries, advanced endometriosis, benign ovarian tumors ...
Breaking Biology Technology:
(Date:2/11/2016)... , Feb. 11, 2016  According to new research ... mainstream. More than 200 fingerprint, iris, and eye-vein ... under 70 brand names. This includes market leaders ... ZTE. Acuity projects that 600 million biometric smartphones ... global installed base. Maxine Most , ...
(Date:2/11/2016)... , Feb. 11, 2016  Vigilant Solutions announces today that ... are being used by Lee,s Summit ... recent location and arrest of a homicide suspect. ... covers around 65 square miles and is home to ... Department has a single mobile license plate reader system and ...
(Date:2/10/2016)... PUNE, India , February 10, 2016 ... --> According to 2016 iris ... fingerprint identification iris recognition is more widely ... are available with both fingerprint and iris ... allows the user to avoid purchasing two ...
Breaking Biology News(10 mins):